VYNE CSO presents InhiBET platform at B&T Cell-Mediated Autoimmune Conference

VYNE Therapeutics Inc.

CSO Iain Stuart, Ph.D., presented at B&T Cell-Mediated Autoimmune Disease Drug Development Conference on July 27, 2022.
Presentation covered the InhiBET platform for bromodomain & end terminal (BET) inhibitors in autoimmune disease.
No new clinical data, financial results, or guidance changes disclosed in the filing or presentation exhibit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.